<!DOCTYPE html>
<html lang="en-us">
  <head>
	<meta name="generator" content="Hugo 0.85.0" />
    <meta charset="utf-8">
    <meta name="viewport" content="width=device-width, initial-scale=1">
    
    <title>fallingstar-Daily-rss | Fallingstar Daily R</title>
    <link rel="stylesheet" href="/css/style.css" />
    <link rel="stylesheet" href="/css/fonts.css" />
    <link href="//cdn.bootcss.com/highlight.js/9.12.0/styles/github.min.css" rel="stylesheet">

  </head>

  <body>
    <nav class="header">
      <div class="banner">
<a href="/" class="text">
&Ffr;&Afr;&Lfr;&Lfr;&Ifr;&Nfr;&Gfr;&Sfr;&Tfr;&Afr;&Rfr; &Dfr;&Afr;&Ifr;&Lfr;&Yfr; &Rfr;
</a>
</div>

      <div class="head-meta">
      
        <span>fallingstar-Daily-rss</span>
        <span>2024-09-28</span>
      
      </div>
    </nav>


<div class="container">
<main class="list">

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39327770/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240927184334&amp;v=2.18.0.post9&#43;e462414">Assessing the hierarchical beta-binomial model as a basic information sharing tool in basket trials</a></h1>
  <div class="date-author">
    
    <span class="date">2024-09-27</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39327770-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240927184334-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    The majority of statistical methods to share information in basket trials are based on a Bayesian hierarchical model with a common normal distribution for the logit-transformed response rates. The methods are of varying complexity, yet they all use this basic model. Generally, complexity is an obstacle for the application in clinical trials and that includes the use of the logit-transformation. The transformation complicates the model and impedes a direct interpretation of the &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39327798/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240927184334&amp;v=2.18.0.post9&#43;e462414">Mechanisms behind the high mortality rate in chronic Chagas cardiomyopathy: Unmasking a three-headed monster</a></h1>
  <div class="date-author">
    
    <span class="date">2024-09-27</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39327798-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240927184334-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    Chagas disease is a neglected tropical disease caused by the parasite Trypanosoma cruzi. Chronic Chagas cardiomyopathy (CCC), the most severe form of target organ involvement in Chagas disease, is characterized by a complex pathophysiology and a unique phenotype that differentiates it from other cardiomyopathies, highlighting its worse prognosis compared to other aetiologies of heart failure. The three pathophysiological mechanisms with the largest impact on this differential mortality &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39327800/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240927184334&amp;v=2.18.0.post9&#43;e462414">Bending the rules: A novel approach to laryngeal surgery in a body donor study</a></h1>
  <div class="date-author">
    
    <span class="date">2024-09-27</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39327800-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240927184334-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSION: The sMAC system effectively addresses challenges associated with transoral laryngeal surgery. Ongoing development aims to overcome current limitations of the system and prepare first clinical &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39327800/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240928190145&amp;v=2.18.0.post9&#43;e462414">Bending the rules: A novel approach to laryngeal surgery in a body donor study</a></h1>
  <div class="date-author">
    
    <span class="date">2024-09-27</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39327800-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240928190145-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSION: The sMAC system effectively addresses challenges associated with transoral laryngeal surgery. Ongoing development aims to overcome current limitations of the system and prepare first clinical &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39328074/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240927184334&amp;v=2.18.0.post9&#43;e462414">Meeting the Needs of People With Severe Quadriplegia in the 21st Century: The Case for Implanted Brain-Computer Interfaces</a></h1>
  <div class="date-author">
    
    <span class="date">2024-09-27</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39328074-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240927184334-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSION: Most importantly, the gap in digital equality fundamentally undermines the basic human rights of people with severe &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39328074/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240928190145&amp;v=2.18.0.post9&#43;e462414">Meeting the Needs of People With Severe Quadriplegia in the 21st Century: The Case for Implanted Brain-Computer Interfaces</a></h1>
  <div class="date-author">
    
    <span class="date">2024-09-27</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39328074-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240928190145-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSION: Most importantly, the gap in digital equality fundamentally undermines the basic human rights of people with severe &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39329071/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240927184334&amp;v=2.18.0.post9&#43;e462414">Effectiveness of the Medical Chatbot PROSCA to Inform Patients About Prostate Cancer: Results of a Randomized Controlled Trial</a></h1>
  <div class="date-author">
    
    <span class="date">2024-09-27</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39329071-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240927184334-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS AND CLINICAL IMPLICATIONS: With the introduction of the PROSCA chatbot, we created and evaluated an innovative, evidence-based AI health information tool as an additional source of information for PC. Our RCT results showed significant benefits of the chatbot in reducing patients' information needs and enhancing their understanding of PC. This easy-to-use AI tool provides accurate, timely, and accessible support, demonstrating its value in the PC diagnosis process. Future &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39329071/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240928190145&amp;v=2.18.0.post9&#43;e462414">Effectiveness of the Medical Chatbot PROSCA to Inform Patients About Prostate Cancer: Results of a Randomized Controlled Trial</a></h1>
  <div class="date-author">
    
    <span class="date">2024-09-27</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39329071-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240928190145-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS AND CLINICAL IMPLICATIONS: With the introduction of the PROSCA chatbot, we created and evaluated an innovative, evidence-based AI health information tool as an additional source of information for PC. Our RCT results showed significant benefits of the chatbot in reducing patients' information needs and enhancing their understanding of PC. This easy-to-use AI tool provides accurate, timely, and accessible support, demonstrating its value in the PC diagnosis process. Future &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39329251/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240927184334&amp;v=2.18.0.post9&#43;e462414">A Negatively Curved Nanographene with Four Embedded Heptagons</a></h1>
  <div class="date-author">
    
    <span class="date">2024-09-27</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39329251-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240927184334-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    Negatively curved nanographenes are considered as cutouts of three-dimensional fully spÂ²-hybridized carbon allotropes such as Schwarzites. Here we present the synthesis of a C(76) cut-out of the Schwarzite 8-4-1-p proposed by Lenosky et al. and investigate its optical as well as electrochemical properties. Furthermore, supramolecular interactions with fullerenes C(60) and C(70) were &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39329251/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240928190145&amp;v=2.18.0.post9&#43;e462414">A Negatively Curved Nanographene with Four Embedded Heptagons</a></h1>
  <div class="date-author">
    
    <span class="date">2024-09-27</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39329251-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240928190145-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    Negatively curved nanographenes are considered as cutouts of three-dimensional fully spÂ²-hybridized carbon allotropes such as Schwarzites. Here we present the synthesis of a C(76) cut-out of the Schwarzite 8-4-1-p proposed by Lenosky et al. and investigate its optical as well as electrochemical properties. Furthermore, supramolecular interactions with fullerenes C(60) and C(70) were &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39329430/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240927184334&amp;v=2.18.0.post9&#43;e462414">Exploring PKG signaling as a therapeutic avenue for pressure overload, ischemia, and HFpEF</a></h1>
  <div class="date-author">
    
    <span class="date">2024-09-27</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39329430-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240927184334-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    INTRODUCTION: Heart failure (HF) is a complex and heterogeneous syndrome resulting from any diastolic or systolic dysfunction of the cardiac muscle. In addition to comorbid conditions, pressure overload, and myocardial ischemia are associated with cardiac remodeling which manifests as extracellular matrix (ECM) perturbations, impaired cellular responses, and subsequent ventricular &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39329430/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240928190145&amp;v=2.18.0.post9&#43;e462414">Exploring PKG signaling as a therapeutic avenue for pressure overload, ischemia, and HFpEF</a></h1>
  <div class="date-author">
    
    <span class="date">2024-09-27</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39329430-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240928190145-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    INTRODUCTION: Heart failure (HF) is a complex and heterogeneous syndrome resulting from any diastolic or systolic dysfunction of the cardiac muscle. In addition to comorbid conditions, pressure overload, and myocardial ischemia are associated with cardiac remodeling which manifests as extracellular matrix (ECM) perturbations, impaired cellular responses, and subsequent ventricular &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39329449/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240927184334&amp;v=2.18.0.post9&#43;e462414">DNA methylation as a new tool for the differential diagnosis between T-LBL and lymphocyte-rich thymoma</a></h1>
  <div class="date-author">
    
    <span class="date">2024-09-27</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39329449-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240927184334-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    T-lymphoblastic lymphoma (T-LBL) and thymoma are two rare primary tumors of the thymus deriving either from T-cell precursors or from thymic epithelial cells, respectively. Some thymoma subtypes (AB, B1, and B2) display numerous reactive terminal deoxynucleotidyl transferase-positive (TdT^(+)) T-cell precursors masking epithelial tumor cells. Therefore, the differential diagnosis between T-LBL and TdT^(+) T-lymphocyte-rich thymoma could be challenging, especially in the case of needle biopsy. &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39329449/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240928190145&amp;v=2.18.0.post9&#43;e462414">DNA methylation as a new tool for the differential diagnosis between T-LBL and lymphocyte-rich thymoma</a></h1>
  <div class="date-author">
    
    <span class="date">2024-09-27</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39329449-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240928190145-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    T-lymphoblastic lymphoma (T-LBL) and thymoma are two rare primary tumors of the thymus deriving either from T-cell precursors or from thymic epithelial cells, respectively. Some thymoma subtypes (AB, B1, and B2) display numerous reactive terminal deoxynucleotidyl transferase-positive (TdT^(+)) T-cell precursors masking epithelial tumor cells. Therefore, the differential diagnosis between T-LBL and TdT^(+) T-lymphocyte-rich thymoma could be challenging, especially in the case of needle biopsy. &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39330692/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240927184334&amp;v=2.18.0.post9&#43;e462414">How Far Is the Nanocellulose Chip and Its Production in Reach? A Literature Survey</a></h1>
  <div class="date-author">
    
    <span class="date">2024-09-27</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39330692-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240927184334-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    The slowdown of Moore&rsquo;s Law necessitates an exploration of novel computing methodologies, new materials, and advantages in chip design. Thus, carbon-based materials have promise for more energy-efficient computing systems in the future. Moreover, sustainability emerges as a new concern for the semiconductor industry. The production and recycling processes associated with current chips present huge environmental challenges. Electronic waste is a major problem, and sustainable solutions &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39330692/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240928190145&amp;v=2.18.0.post9&#43;e462414">How Far Is the Nanocellulose Chip and Its Production in Reach? A Literature Survey</a></h1>
  <div class="date-author">
    
    <span class="date">2024-09-27</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39330692-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240928190145-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    The slowdown of Moore&rsquo;s Law necessitates an exploration of novel computing methodologies, new materials, and advantages in chip design. Thus, carbon-based materials have promise for more energy-efficient computing systems in the future. Moreover, sustainability emerges as a new concern for the semiconductor industry. The production and recycling processes associated with current chips present huge environmental challenges. Electronic waste is a major problem, and sustainable solutions &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39330962/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&amp;fc=20211015124055&amp;ff=20240927184326&amp;v=2.18.0.post9&#43;e462414">Celebrating Public Health</a></h1>
  <div class="date-author">
    
    <span class="date">2024-09-27</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39330962-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1lik-026y9bjre4xdq231bsa89bny4o2rfi-9wxqd8c31c6cqe-fc-20211015124055-ff-20240927184326-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    No &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39330962/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&amp;fc=20211015124055&amp;ff=20240928190141&amp;v=2.18.0.post9&#43;e462414">Celebrating Public Health</a></h1>
  <div class="date-author">
    
    <span class="date">2024-09-27</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39330962-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1lik-026y9bjre4xdq231bsa89bny4o2rfi-9wxqd8c31c6cqe-fc-20211015124055-ff-20240928190141-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    No &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39330966/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&amp;fc=20211015124055&amp;ff=20240927184326&amp;v=2.18.0.post9&#43;e462414">Fractional Doses of Pneumococcal Conjugate Vaccine - A Noninferiority Trial</a></h1>
  <div class="date-author">
    
    <span class="date">2024-09-27</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39330966-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1lik-026y9bjre4xdq231bsa89bny4o2rfi-9wxqd8c31c6cqe-fc-20211015124055-ff-20240927184326-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: In a three-dose schedule (two primary doses and a booster), 40% doses of PCV13 were noninferior to full doses for all included serotypes. Lower doses of PCV13 and PCV10 did not meet the criteria for noninferiority. (Funded by the Bill and Melinda Gates Foundation and others; ClinicalTrials.gov number, NCT03489018; Pan African Clinical Trial Registry number, PACTR202104717648755.). &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39330966/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&amp;fc=20211015124055&amp;ff=20240928190141&amp;v=2.18.0.post9&#43;e462414">Fractional Doses of Pneumococcal Conjugate Vaccine - A Noninferiority Trial</a></h1>
  <div class="date-author">
    
    <span class="date">2024-09-27</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39330966-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1lik-026y9bjre4xdq231bsa89bny4o2rfi-9wxqd8c31c6cqe-fc-20211015124055-ff-20240928190141-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: In a three-dose schedule (two primary doses and a booster), 40% doses of PCV13 were noninferior to full doses for all included serotypes. Lower doses of PCV13 and PCV10 did not meet the criteria for noninferiority. (Funded by the Bill and Melinda Gates Foundation and others; ClinicalTrials.gov number, NCT03489018; Pan African Clinical Trial Registry number, PACTR202104717648755.). &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39331066/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240927184334&amp;v=2.18.0.post9&#43;e462414">Reconstruction of severe acetabular defects (Paprosky type III A) in total hip arthroplasty using modular tantalum augments in combination with a cemented cup</a></h1>
  <div class="date-author">
    
    <span class="date">2024-09-27</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39331066-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240927184334-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: This study has demonstrated good mid-term (mean 4.5 years) clinical and radiological outcomes of modular tantalum TM augments in combination with a cemented cup for the reconstruction of major acetabular defects. Mean blood tantalum concentrations were increased in patients with stable tantalum implants compared to healthy &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39331066/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240928190145&amp;v=2.18.0.post9&#43;e462414">Reconstruction of severe acetabular defects (Paprosky type III A) in total hip arthroplasty using modular tantalum augments in combination with a cemented cup</a></h1>
  <div class="date-author">
    
    <span class="date">2024-09-27</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39331066-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240928190145-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: This study has demonstrated good mid-term (mean 4.5 years) clinical and radiological outcomes of modular tantalum TM augments in combination with a cemented cup for the reconstruction of major acetabular defects. Mean blood tantalum concentrations were increased in patients with stable tantalum implants compared to healthy &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39331123/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240927184334&amp;v=2.18.0.post9&#43;e462414">Discovery of BAY-405: An Azaindole-Based MAP4K1 Inhibitor for the Enhancement of T-Cell Immunity against Cancer</a></h1>
  <div class="date-author">
    
    <span class="date">2024-09-27</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39331123-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240927184334-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    Mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1) is a serine/threonine kinase that acts as an immune checkpoint downstream of T-cell receptor stimulation. MAP4K1 activity is enhanced by prostaglandin E2 (PGE2) and transforming growth factor beta (TGFÎ²), immune modulators commonly present in the tumor microenvironment. Therefore, its pharmacological inhibition is an attractive immuno-oncology concept for inducing therapeutic T-cell responses in cancer patients. Here, we &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39331123/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240928190145&amp;v=2.18.0.post9&#43;e462414">Discovery of BAY-405: An Azaindole-Based MAP4K1 Inhibitor for the Enhancement of T-Cell Immunity against Cancer</a></h1>
  <div class="date-author">
    
    <span class="date">2024-09-27</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39331123-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240928190145-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    Mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1) is a serine/threonine kinase that acts as an immune checkpoint downstream of T-cell receptor stimulation. MAP4K1 activity is enhanced by prostaglandin E2 (PGE2) and transforming growth factor beta (TGFÎ²), immune modulators commonly present in the tumor microenvironment. Therefore, its pharmacological inhibition is an attractive immuno-oncology concept for inducing therapeutic T-cell responses in cancer patients. Here, we &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39331528/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240928190145&amp;v=2.18.0.post9&#43;e462414">Long-term outcome of the Milano-HART strategy for high-risk medulloblastoma, including the impact of molecular subtype</a></h1>
  <div class="date-author">
    
    <span class="date">2024-09-27</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39331528-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240928190145-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: This strategy, partly adopted in the ongoing SIOPE protocol,confirmed improved EFS and OS over previously reported outcomes in all high-risk categories;SHH tumors appeared the most &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39331673/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240928190145&amp;v=2.18.0.post9&#43;e462414">GPMelt: A hierarchical Gaussian process framework to explore the dark meltome of thermal proteome profiling experiments</a></h1>
  <div class="date-author">
    
    <span class="date">2024-09-27</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39331673-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240928190145-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    Thermal proteome profiling (TPP) is a proteome wide technology that enables unbiased detection of protein drug interactions as well as changes in post-translational state of proteins between different biological conditions. Statistical analysis of temperature range TPP (TPP-TR) datasets relies on comparing protein melting curves, describing the amount of non-denatured proteins as a function of temperature, between different conditions (e.g. presence or absence of a drug). &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39331724/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=7603509&amp;fc=None&amp;ff=20240928190140&amp;v=2.18.0.post9&#43;e462414">Daratumumab with lenalidomide as maintenance after transplant in newly diagnosed multiple myeloma: the AURIGA study</a></h1>
  <div class="date-author">
    
    <span class="date">2024-09-27</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39331724-utm-source-curl-utm-medium-rss-utm-campaign-journals-utm-content-7603509-fc-none-ff-20240928190140-v-2-18-0-post9-e462414/">
    
    
    
    
    
      
    
    No randomized trial has directly compared daratumumab and lenalidomide (D-R) maintenance therapy versus standard-of-care lenalidomide (R) alone post-transplant. Here, we report the primary results of the phase 3 AURIGA study evaluating D-R versus R maintenance in NDMM patients who were in â‰¥very good partial response, minimal residual disease (MRD; threshold 10-5) positive, and anti-CD38 naÃ¯ve post-transplant. Patients were randomized 1:1 to D-R or R maintenance for up to 36 cycles. Two &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39331727/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240928190145&amp;v=2.18.0.post9&#43;e462414">Twin study identifies early immunological and metabolic dysregulation of CD8&lt;sup&gt;&#43;&lt;/sup&gt; T cells in multiple sclerosis</a></h1>
  <div class="date-author">
    
    <span class="date">2024-09-27</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39331727-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240928190145-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    Multiple sclerosis (MS) is an inflammatory neurological disease of the central nervous system with a subclinical phase preceding frank neuroinflammation. CD8^(+) T cells are abundant within MS lesions, but their potential role in disease pathology remains unclear. Using high-throughput single-cell RNA sequencing and single-cell T cell receptor analysis, we compared CD8^(+) T cell clones from the blood and cerebrospinal fluid (CSF) of monozygotic twin pairs in which the cotwin had either no &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39332409/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240928190145&amp;v=2.18.0.post9&#43;e462414">Common variants increase risk for congenital diaphragmatic hernia within the context of de novo variants</a></h1>
  <div class="date-author">
    
    <span class="date">2024-09-27</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39332409-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240928190145-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    Congenital diaphragmatic hernia (CDH) is a severe congenital anomaly often accompanied by other structural anomalies and/or neurobehavioral manifestations. Rare de novo protein-coding variants and copy-number variations contribute to CDH in the population. However, most individuals with CDH remain genetically undiagnosed. Here, we perform integrated de novo and common-variant analyses using 1,469 CDH individuals, including 1,064 child-parent trios and 6,133 ancestry-matched, unaffected &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39332586/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240928190145&amp;v=2.18.0.post9&#43;e462414">Integration of Transcriptomics, Proteomics and Loss-of-function Screening Reveals WEE1 as a Target for Combination with Dasatinib against Proneural Glioblastoma</a></h1>
  <div class="date-author">
    
    <span class="date">2024-09-27</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39332586-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240928190145-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    Glioblastoma is characterized by a pronounced resistance to therapy with dismal prognosis. Transcriptomics classify glioblastoma into proneural (PN), mesenchymal (MES) and classical (CL) subtypes that show differential resistance to targeted therapies. The aim of this study was to provide a viable approach for identifying combination therapies in glioblastoma subtypes. Proteomics and phosphoproteomics were performed on dasatinib inhibited glioblastoma stem cells (GSCs) and complemented by &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39332691/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240928190145&amp;v=2.18.0.post9&#43;e462414">Role of the RNA binding protein IGF2BP1 in cancer multidrug resistance</a></h1>
  <div class="date-author">
    
    <span class="date">2024-09-27</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39332691-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240928190145-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    The insulin-like growth factor-2 mRNA-binding protein 1 (IGF2BP1), a member of a conserved family of single-stranded RNA-binding proteins (IGF2BP1-3), is expressed in a broad range of fetal tissues, placenta and more than sixteen cancer types but only in a limited number of normal adult tissues. IGF2BP1is required for the transport from nucleus to cytoplasm of certain mRNAs that play essential roles in embryogenesis, carcinogenesis, and multidrug resistance (MDR), by affecting their &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39332710/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240928190145&amp;v=2.18.0.post9&#43;e462414">DNA methylation profiling of salivary gland tumors supports and expands conventional classification</a></h1>
  <div class="date-author">
    
    <span class="date">2024-09-27</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39332710-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240928190145-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    Tumors of the major and minor salivary gland histologically encompass a diverse and partly overlapping spectrum of frequently diagnostically challenging neoplasms. Despite recent advances in molecular testing and the identification of tumor-specific mutations or gene fusions, there is an unmet need to identify additional diagnostic biomarkers for entities lacking specific alterations. In this study, we collected a comprehensive cohort of 363 cases encompassing 20 different salivary gland &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39332820/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240928190145&amp;v=2.18.0.post9&#43;e462414">Breaking Strong Alkynyl-Phenyl Bonds: Poly(&lt;em&gt;para&lt;/em&gt;-phenylene ethynylene)s under Mechanical Stress</a></h1>
  <div class="date-author">
    
    <span class="date">2024-09-27</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39332820-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240928190145-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    Stronger chemical bonds withstand higher mechanical forces; thus, the rupture of single bonds is preferred over the rupture of double or triple bonds or aromatic rings. We investigated bond scission in poly(dialkyl-p-phenylene ethynylene)s (PPEs), a fully conjugated polymer. In a scale-bridging approach using electron-paramagnetic resonance spectroscopy and gel permeation chromatography of cryomilled samples, in combination with density functional theory calculations and &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39332899/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240928190145&amp;v=2.18.0.post9&#43;e462414">Early stopping versus continued retrievals after failed recanalization: associated factors and implications for outcome</a></h1>
  <div class="date-author">
    
    <span class="date">2024-09-27</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39332899-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240928190145-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSION: The probability of early stopping was higher in patients with clinical conditions associated with: a) Favorable prognosis and assumed lower impact of recanalization success on functional status, such as distal occlusions; and b) Unfavorable prognosis, such as higher age and reduced pre-stroke functional status. Adverse events during the procedure increased the probability of early stopping. The number of recanalization attempts did not increase the risk of unfavorable outcome &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39333300/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240928190145&amp;v=2.18.0.post9&#43;e462414">Thanks to the ABC reviewers in 2024</a></h1>
  <div class="date-author">
    
    <span class="date">2024-09-27</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39333300-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240928190145-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    No &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39333498/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240928190145&amp;v=2.18.0.post9&#43;e462414">Phosphoproteomics-directed manipulation reveals SEC22B as a hepatocellular signaling node governing metabolic actions of glucagon</a></h1>
  <div class="date-author">
    
    <span class="date">2024-09-27</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39333498-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240928190145-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    The peptide hormone glucagon is a fundamental metabolic regulator that is also being considered as a pharmacotherapeutic option for obesity and type 2 diabetes. Despite this, we know very little regarding how glucagon exerts its pleiotropic metabolic actions. Given that the liver is a chief site of action, we performed in situ time-resolved liver phosphoproteomics to reveal glucagon signaling nodes. Through pathway analysis of the thousands of phosphopeptides identified, we reveal &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1251560221/OyTL3i4rv">æ–°å† ç–«è‹—æˆ–æé«˜è‚¿ç˜¤æ‚£è€…æ€»ä½“ç”Ÿå­˜ã€‚ä»Šå¤©Biocenturyè®²åˆ°äº†2024å¹´ESMOï¼ˆæ¬§æ´²è‚¿ç˜¤å­¦ä¼šå¹´ä¼šï¼‰ä¸€ä¸ªéå¸¸æœ‰æ„æ€çš„æ¥è‡ªMD Andersonçš„ç ”ç©¶ï¼ˆæ‘˜è¦995 MOï¼‰ï¼Œè¯¥ç ”ç©¶å‘ç°æ¥ç§...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-09-27</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1251560221-oytl3i4rv/">
    
    
    
    
    
      
    
    æ–°å† ç–«è‹—æˆ–æé«˜è‚¿ç˜¤æ‚£è€…æ€»ä½“ç”Ÿå­˜ã€‚ä»Šå¤©Biocenturyè®²åˆ°äº†2024å¹´ESMOï¼ˆæ¬§æ´²è‚¿ç˜¤å­¦ä¼šå¹´ä¼šï¼‰ä¸€ä¸ªéå¸¸æœ‰æ„æ€çš„æ¥è‡ªMD Andersonçš„ç ”ç©¶ï¼ˆæ‘˜è¦995 MOï¼‰ï¼Œè¯¥ç ”ç©¶å‘ç°æ¥ç§äº†æ–°å† COVID mRNAç–«è‹—çš„è½¬ç§»æ¶æ€§é»‘è‰²ç´ ç˜¤æ‚£è€…æ€»ä½“ç”Ÿå­˜ç‡ï¼ˆOSï¼‰æé«˜ã€ç–¾ç—…è¿›å±•å»¶ç¼“ï¼ˆå½“ç„¶ï¼Œç»Ÿè®¡åˆ†æçš„æ—¶å€™è¦é™¤å¤–COVID mRNAå‡å°‘æ‚£è€…å‘ç”ŸCOVIDå¯¹æ‚£è€…é¢„åçš„å½±å“ï¼‰ã€‚ç ”ç©¶è¿›ä¸€æ­¥å‘ç°æ¥ç§COVID-19 mRNAç–«è‹—éå°ç»†èƒè‚ºç™Œæ‚£è€…ï¼ˆNSCLCï¼‰åœ¨æ¥ç§ç–«è‹—100å¤©å†…åšç©¿åˆºæ´»æ£€ï¼Œç–«è‹—æ¥ç§è€…è‚¿ç˜¤ç»„ç»‡PD-L1è¡¨è¾¾ä¸Šè°ƒï¼Œå› æ­¤å¯¹PD-1/PD-L1æ‹®æŠ—å‰‚åº”ç­”æ›´å¥½ã€‚<!-- raw HTML omitted --><!-- raw HTML omitted -->æˆ‘ä¸Šä¸€ä¸ªå·¥ä½œç ”ç©¶mRNAç–«è‹—åœ¨æ–°å† COVIDå’ŒHIVä¸­çš„åº”ç”¨ã€‚2022å¹´åº•ï¼ŒMerckå’ŒModernaæŠ¥é“äº†å…¶è‚¿ç˜¤æ²»ç–—mRNAç–«è‹—mRNA-4157å’ŒKeytrudaè”åˆæ²»ç–—å°†III/IVæœŸæ¶æ€§é»‘è‰²ç´ ç˜¤æ­»äº¡å’Œå¤å‘é™ä½44%çš„2æœŸä¸´åºŠè¯•éªŒç»“æœï¼Œè¿™ä¸€ç»“æœåœ¨2023å¹´AACRä¸Šè¢«è¿›ä¸€æ­¥æŠ¥é“ï¼ˆ&lt;a &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1251560221/OyZyNfMxa">ç¾å›½å«ç”Ÿéƒ¨åˆå¼€å§‹å…è´¹å‘æ”¾COVIDæ£€æµ‹è¯•å‰‚ç›’äº†ï¼Œæ¯å®¶å¯ä»¥é¢†4ä¸ªï¼ŒUSPSå…è´¹é‚®å¯„ç½‘ç«™é“¾æ¥ï¼šç½‘é¡µé“¾æ¥ - è½¬å‘ @å­é™µåœ¨å¬æ­Œ:&amp;ensp;é‡è¦çš„ä¿¡æ¯ã€‚ç¾å›½å¤å­£ç»å†äº†ä¸€ä¸ªCOVID...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-09-27</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1251560221-oyzynfmxa/">
    
    
    
    
    
      
    
    ç¾å›½å«ç”Ÿéƒ¨åˆå¼€å§‹å…è´¹å‘æ”¾COVIDæ£€æµ‹è¯•å‰‚ç›’äº†ï¼Œæ¯å®¶å¯ä»¥é¢†4ä¸ªï¼ŒUSPSå…è´¹é‚®å¯„ç½‘ç«™é“¾æ¥ï¼š<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->ç½‘é¡µé“¾æ¥<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --> - è½¬å‘ <!-- raw HTML omitted -->@å­é™µåœ¨å¬æ­Œ<!-- raw HTML omitted -->:â€‚é‡è¦çš„ä¿¡æ¯ã€‚ç¾å›½å¤å­£ç»å†äº†ä¸€ä¸ªCOVIDç–«æƒ…å°é«˜å³°ï¼Œè™½ç„¶æœ€è¿‘COVIDç–«æƒ…æœ‰æ‰€ç¼“è§£ï¼Œä½†ç™½å®«å®£å¸ƒè‡ª9æœˆ25æ—¥å°†é‡æ–°å¼€å§‹å…è´¹å‘ç¾å›½å±…æ°‘å‘æ”¾æ£€æµ‹è¯•å‰‚ç›’ï¼Œæ¯å®¶ï¼ˆhouseholdï¼‰å¯ä»¥é¢†å–4ä¸ªã€‚é¢†å–ç½‘ç«™ä¸åŸæ¥ä¸€æ ·ï¼š&lt;a &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1671109627/OyXEmieLx">ğŸ”»è¯´çœŸçš„ï¼Œæ—¥æœ¬äººé€‰è°éƒ½æ˜¯ä¹å­ã€‚ğŸ”»æ¯”å¦‚ï¼Œè¿™æ˜¯æ€§è½¬ä¸œæ¡äºŒç­‰å…µé­”æ€”äººé«˜å¸‚æ—©è‹—æ¼”å”±çš„ã€ŠRusty Nailã€‹#çŸ³ç ´èŒ‚å°†å‡ºä»»æ—¥æœ¬é¦–ç›¸##çƒ­é—¨è§†é¢‘# åŒ…å®¹ä¸‡ç‰©æ’æ²³æ°´çš„å¾®åšè§†...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-09-27</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1671109627-oyxemielx/">
    
    
    
    
    
      
    
    ğŸ”»è¯´çœŸçš„ï¼Œæ—¥æœ¬äººé€‰è°éƒ½æ˜¯ä¹å­ã€‚<!-- raw HTML omitted -->ğŸ”»æ¯”å¦‚ï¼Œè¿™æ˜¯æ€§è½¬ä¸œæ¡äºŒç­‰å…µé­”æ€”äººé«˜å¸‚æ—©è‹—æ¼”å”±çš„ã€ŠRusty Nailã€‹<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->#çŸ³ç ´èŒ‚å°†å‡ºä»»æ—¥æœ¬é¦–ç›¸#<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;span &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1671109627/OyXGIhJ3k">ğŸ”»è«ä¼Šè°¢è€¶å¤«èŠ­è•¾èˆå›¢æ¼”å‘˜çš„æ¼‚æµ®èˆè¹ˆæŠ€å·§ã€‚#çƒ­é—¨è§†é¢‘# åŒ…å®¹ä¸‡ç‰©æ’æ²³æ°´çš„å¾®åšè§†é¢‘</a></h1>
  <div class="date-author">
    
    <span class="date">2024-09-27</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1671109627-oyxgihj3k/">
    
    
    
    
    
      
    
    ğŸ”»è«ä¼Šè°¢è€¶å¤«èŠ­è•¾èˆå›¢æ¼”å‘˜çš„æ¼‚æµ®èˆè¹ˆæŠ€å·§ã€‚<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->#çƒ­é—¨è§†é¢‘#<!-- raw HTML omitted --><!-- raw HTML omitted --> <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->åŒ…å®¹ä¸‡ç‰©æ’æ²³æ°´çš„å¾®åšè§†é¢‘<!-- raw HTML omitted --><!-- raw HTML omitted --> <!-- raw HTML omitted -->&lt;div style=&ldquo;clear: &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1671109627/OyXIjwvVk">ğŸ”»ç¾å›½æµ·å²¸è­¦å«é˜Ÿåœ¨æµ·ä¼¦é£“é£æ¥ä¸´ä¹‹å‰ï¼Œä»ä¸€æ¡å¤±æ§å¸†èˆ¹ä¸Šæ•‘äº†ä¸€ä¸ªäººå’Œä»–çš„ç‹—ã€‚ğŸ”»via uscoastguard#çƒ­é—¨è§†é¢‘# åŒ…å®¹ä¸‡ç‰©æ’æ²³æ°´çš„å¾®åšè§†é¢‘</a></h1>
  <div class="date-author">
    
    <span class="date">2024-09-27</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1671109627-oyxijwvvk/">
    
    
    
    
    
      
    
    ğŸ”»ç¾å›½æµ·å²¸è­¦å«é˜Ÿåœ¨æµ·ä¼¦é£“é£æ¥ä¸´ä¹‹å‰ï¼Œä»ä¸€æ¡å¤±æ§å¸†èˆ¹ä¸Šæ•‘äº†ä¸€ä¸ªäººå’Œä»–çš„ç‹—ã€‚<!-- raw HTML omitted -->ğŸ”»via uscoastguard<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->#çƒ­é—¨è§†é¢‘#<!-- raw HTML omitted --><!-- raw HTML omitted --> <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->åŒ…å®¹ä¸‡ç‰©æ’æ²³æ°´çš„å¾®åšè§†é¢‘<!-- raw HTML omitted --><!-- raw HTML omitted --> &lt;br &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1671109627/OyXJgCn65">ğŸ”»éº»ç”Ÿå¤ªéƒæ˜¯ä¸æ˜¯ç©ä¸èµ·ï¼Ÿ#çŸ³ç ´èŒ‚å°†å‡ºä»»æ—¥æœ¬é¦–ç›¸##çƒ­é—¨è§†é¢‘# åŒ…å®¹ä¸‡ç‰©æ’æ²³æ°´çš„å¾®åšè§†é¢‘</a></h1>
  <div class="date-author">
    
    <span class="date">2024-09-27</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1671109627-oyxjgcn65/">
    
    
    
    
    
      
    
    ğŸ”»éº»ç”Ÿå¤ªéƒæ˜¯ä¸æ˜¯ç©ä¸èµ·ï¼Ÿ<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->#çŸ³ç ´èŒ‚å°†å‡ºä»»æ—¥æœ¬é¦–ç›¸#<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->#çƒ­é—¨è§†é¢‘#<!-- raw HTML omitted --><!-- raw HTML omitted --> &lt;a href=&ldquo;<a href="https://video.weibo">https://video.weibo</a>. &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1671109627/OyXJjFbBQ">ğŸ”»åœ¨ğŸ‡°ğŸ‡µæœé²œä¸œæµ·è¾¹å’¸å…´é™„è¿‘é£æ™¯ç§€ä¸½çš„é©¬åº„æµ·æ°´æµ´åœºå†æ¬¡å‘å¤–å›½æ¸¸å®¢å¼€æ”¾ã€‚ğŸ”»via vk#çƒ­é—¨è§†é¢‘# åŒ…å®¹ä¸‡ç‰©æ’æ²³æ°´çš„å¾®åšè§†é¢‘</a></h1>
  <div class="date-author">
    
    <span class="date">2024-09-27</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1671109627-oyxjjfbbq/">
    
    
    
    
    
      
    
    ğŸ”»åœ¨ğŸ‡°ğŸ‡µæœé²œä¸œæµ·è¾¹å’¸å…´é™„è¿‘é£æ™¯ç§€ä¸½çš„é©¬åº„æµ·æ°´æµ´åœºå†æ¬¡å‘å¤–å›½æ¸¸å®¢å¼€æ”¾ã€‚<!-- raw HTML omitted -->ğŸ”»via vk<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->#çƒ­é—¨è§†é¢‘#<!-- raw HTML omitted --><!-- raw HTML omitted --> <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->åŒ…å®¹ä¸‡ç‰©æ’æ²³æ°´çš„å¾®åšè§†é¢‘<!-- raw HTML omitted --><!-- raw HTML omitted --> <!-- raw HTML omitted -->&lt;div &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1671109627/OyXKDbs4n">ğŸ”»åˆ«è¿™æ ·ï¼Œå“¥ä»¬å„¿#Aè‚¡æ­£ä»åå¼¹èµ°å‘åè½¬# [å›¾ç‰‡]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-09-27</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1671109627-oyxkdbs4n/">
    
    
    
    
    
      
    
    ğŸ”»åˆ«è¿™æ ·ï¼Œå“¥ä»¬å„¿<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->#Aè‚¡æ­£ä»åå¼¹èµ°å‘åè½¬#<!-- raw HTML omitted --><!-- raw HTML omitted --> <!-- raw HTML omitted --> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1671109627/OyXLH6h4P">ğŸ”»ï¼Ÿæ²¡æœ‰å•Šï¼Ÿ#æ­¦æ±‰éœ‡æ„Ÿ# [å›¾ç‰‡][å›¾ç‰‡]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-09-27</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1671109627-oyxlh6h4p/">
    
    
    
    
    
      
    
    ğŸ”»ï¼Ÿæ²¡æœ‰å•Šï¼Ÿ<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->#æ­¦æ±‰éœ‡æ„Ÿ#<!-- raw HTML omitted --><!-- raw HTML omitted --> <!-- raw HTML omitted --><!-- raw HTML omitted --> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1671109627/OyXOz1GAQ">ğŸ”»ç¼–ç›®é‡Œä¹Ÿæ²¡çœ‹åˆ°ã€‚#æ­¦æ±‰éœ‡æ„Ÿ# [å›¾ç‰‡]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-09-27</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1671109627-oyxoz1gaq/">
    
    
    
    
    
      
    
    ğŸ”»ç¼–ç›®é‡Œä¹Ÿæ²¡çœ‹åˆ°ã€‚<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->#æ­¦æ±‰éœ‡æ„Ÿ#<!-- raw HTML omitted --><!-- raw HTML omitted --> <!-- raw HTML omitted --> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1671109627/OyXW8vtct">ğŸ”»åŠ è—¤èƒœä¿¡ä»Šå¤©ä¸å…¬å¼€æ”¯æŒä»–ç«é€‰è‡ªæ°‘å…šå€™é€‰äººçš„è®®å‘˜ä»¬å…±è¿›åˆé¤ï¼Œåƒäº†ä¸€é¡¿ä¼ ç»Ÿçš„å’–å–±çŒªæ’é¥­ï¼Œåƒé¥­çš„ä¸€å…±æœ‰ 20 äººã€‚ğŸ”»åœ¨ç¬¬ä¸€è½®æŠ•ç¥¨ä¸­ï¼ŒåŠ è—¤åªå¾—åˆ°äº† 16 ç¥¨ï¼Œè¿™...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-09-27</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1671109627-oyxw8vtct/">
    
    
    
    
    
      
    
    ğŸ”»åŠ è—¤èƒœä¿¡ä»Šå¤©ä¸å…¬å¼€æ”¯æŒä»–ç«é€‰è‡ªæ°‘å…šå€™é€‰äººçš„è®®å‘˜ä»¬å…±è¿›åˆé¤ï¼Œåƒäº†ä¸€é¡¿ä¼ ç»Ÿçš„å’–å–±çŒªæ’é¥­ï¼Œåƒé¥­çš„ä¸€å…±æœ‰ 20 äººã€‚<!-- raw HTML omitted -->ğŸ”»åœ¨ç¬¬ä¸€è½®æŠ•ç¥¨ä¸­ï¼ŒåŠ è—¤åªå¾—åˆ°äº† 16 ç¥¨ï¼Œè¿™æ„å‘³ç€æœ‰ 4 ä¸ªåƒäº†å’–å–±çŒªæ’é¥­çš„äººèƒŒå›äº†ä»–ã€‚<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->#çŸ³ç ´èŒ‚å°†å‡ºä»»æ—¥æœ¬é¦–ç›¸#<!-- raw HTML omitted --><!-- raw HTML omitted --> &lt;img style=&quot;&quot; src=&ldquo;<a href="https://tvax2.sinaimg.cn/large/639b1bfbly1hu2m3kx3cxj20qo1bdk2g.jpg%22">https://tvax2.sinaimg.cn/large/639b1bfbly1hu2m3kx3cxj20qo1bdk2g.jpg&quot;</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1671109627/OyXXack5n">åˆæ‡‚å®Œå’¯ï½æ˜¯ä¸æ˜¯è€é©¬æ²¡å¼€æºçš„éƒ½æ˜¯åŠ¨ç”»å•Šï¼Ÿ//@é©¬ä¸€é¾™æ— æ•Œå…‹æ‹‰æ–¯:å›å¤@åäº”ä»Šå¤©çœ‹ä¹¦äº†å—:ç«ç®­æ²¡ç»•æµå•Šï¼Œç©¿è¶Šæœºå¯ä»¥éšæ„çš„æ”€å‡ä¿¯æ‹è¿˜èƒ½åœ¨ç«ç®­ä¸‹é¢ä»°æ‹ï¼Œå±…ç„¶ä¹Ÿæ²¡å—...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-09-27</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1671109627-oyxxack5n/">
    
    
    
    
    
      
    
    åˆæ‡‚å®Œå’¯ï½æ˜¯ä¸æ˜¯è€é©¬æ²¡å¼€æºçš„éƒ½æ˜¯åŠ¨ç”»å•Šï¼Ÿ//<!-- raw HTML omitted -->@é©¬ä¸€é¾™æ— æ•Œå…‹æ‹‰æ–¯<!-- raw HTML omitted -->:å›å¤<!-- raw HTML omitted -->@åäº”ä»Šå¤©çœ‹ä¹¦äº†å—<!-- raw HTML omitted -->:ç«ç®­æ²¡ç»•æµå•Šï¼Œç©¿è¶Šæœºå¯ä»¥éšæ„çš„æ”€å‡ä¿¯æ‹è¿˜èƒ½åœ¨ç«ç®­ä¸‹é¢ä»°æ‹ï¼Œå±…ç„¶ä¹Ÿæ²¡å—åˆ°ç»•æµå½±å“ï¼Œè¿™æ˜¯ä»€ä¹ˆnbè®¾å¤‡ï¼Ÿè€Œä¸”çˆ†ç‚¸ç¬é—´çš„çƒŸé›¾ï¼Œæ„Ÿè§‰å¾ˆå‡â€¦ è€Œä¸”æ•´ä½“çš„ç”»é¢ä¸€ä¸å™ªç‚¹éƒ½æ²¡æœ‰ï¼Œç”šè‡³çˆ†ç‚¸éƒ½æ²¡ï¼Œå¤ªæ‰¯æ·¡äº†//<!-- raw HTML omitted -->@é©¬ä¸€é¾™æ— æ•Œå…‹æ‹‰æ–¯<!-- raw HTML omitted -->:æ˜¾ç„¶å°±æ˜¯åŠ¨ç”»//&lt;a href=&ldquo;<a href="https://weibo.com/n/%E8%A2%AB%E5%8A%A8%E8%A2%AB%E5%8A%25">https://weibo.com/n/%E8%A2%AB%E5%8A%A8%E8%A2%AB%E5%8A%</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/6015489225/OyWrcFcU6">ä¹…ä¿å²ç»ªé‡Œ via.nogizaka_goods [å›¾ç‰‡]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-09-27</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-6015489225-oywrcfcu6/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->ä¹…ä¿å²ç»ªé‡Œ<!-- raw HTML omitted --><!-- raw HTML omitted --> via.nogizaka_goods <!-- raw HTML omitted --> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/6015489225/OyX1MzlBn">ä¹…ä¿å²ç»ªé‡Œ via.ç·’è¡Œè®°fb [å›¾ç‰‡][å›¾ç‰‡]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-09-27</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-6015489225-oyx1mzlbn/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->ä¹…ä¿å²ç»ªé‡Œ<!-- raw HTML omitted --><!-- raw HTML omitted --> via.ç·’è¡Œè®°fb <!-- raw HTML omitted -->&lt;img style=&quot;&quot; src=&ldquo;<a href="https://tvax1.sinaimg.cn/large/006z6nxLgy1hu2i4b3jwsj30u00k">https://tvax1.sinaimg.cn/large/006z6nxLgy1hu2i4b3jwsj30u00k</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/6015489225/OyYVAwBPh">ä¹…ä¿å²ç»ªé‡Œ#ä¹…ä¿å²ç»ªé‡Œæ‰‹æœºåš# 2024.09.25 11:55ã€Œæ¬¸å˜¿å˜¿ã€æ—©ä¸Šå¥½ã€œæƒ³åšçš„äº‹æƒ…ã€å¿…é¡»è¦åšçš„äº‹æƒ…è™½ç„¶å †ç§¯å¦‚å±±ï¼Œä½†æˆ‘æ‰“ç®—å¥½å¥½åˆ©ç”¨æ—¶é—´é€ä¸€æ•´ç†â€¦ï¼ï¼æ—©ä¸Šå¼€å§‹å°±åƒ...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-09-27</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-6015489225-oyyvawbph/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->ä¹…ä¿å²ç»ªé‡Œ<!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;a href=&ldquo;<a href="https://m.weibo.cn/search?containerid=231522type%3D1%26t%3D10%26q%3D%23%E4%B9%85%E4%BF%9D%E5%8F%B2%E7%BB%AA%E9%87%8C%E6%89%8B%E6%9C%BA%E5">https://m.weibo.cn/search?containerid=231522type%3D1%26t%3D10%26q%3D%23%E4%B9%85%E4%BF%9D%E5%8F%B2%E7%BB%AA%E9%87%8C%E6%89%8B%E6%9C%BA%E5</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/6015489225/OyYWth7y5">ä¹…ä¿å²ç»ªé‡Œ#ä¹…ä¿å²ç»ªé‡Œæ‰‹æœºåš# 2024.09.25 11:56(è¡¥)ã€Œå‘œå‘¼å‘¼ã€DARSï¼è¯·ä¸€å®šè¦çœ‹çœ‹å¹¿å‘Šå“¦ã€œï¼ï¼ï¼ä¸€ç›´åœ¨è·³èˆâ˜ºï¸ä¼‘æ¯å®¤é‡Œæˆ‘ä¸€ç›´è·ŸæŸä¸ªå¥³å­©ä¸€ç›´å¾…åœ¨ä¸€èµ·ã€‚å¤§æ¦‚å°±...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-09-27</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-6015489225-oyywth7y5/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->ä¹…ä¿å²ç»ªé‡Œ<!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;a href=&ldquo;<a href="https://m.weibo.cn/search?containerid=231522type%3D1%26t%3D10%26q%3D%23%E4%B9%85%E4%BF%9D%E5%8F%B2%E7%BB%AA%E9%87%8C%E6%89%8B%E6%9C%BA%E5%8D%9A%23&amp;amp;isnewpa">https://m.weibo.cn/search?containerid=231522type%3D1%26t%3D10%26q%3D%23%E4%B9%85%E4%BF%9D%E5%8F%B2%E7%BB%AA%E9%87%8C%E6%89%8B%E6%9C%BA%E5%8D%9A%23&amp;amp;isnewpa</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/6015489225/OyYZz1sX9">ä¹…ä¿å²ç»ªé‡Œ#shiorigram# æ£’çƒå°‘å¥³é¹«å°¾@ comicé¹«å°¾å¸Œæœ›ä¿æŒä¹å¤©æ¼«ç”»ä»Šå¤©å‘å”®â€¦ğŸ‰ç»ˆäºè¦å‘å”®äº†â€¦ï¼ï¼è¯·ä¸€å®šè¦å…¥æ‰‹ğŸ‘€ä¹ƒæœ¨å‚46ANNçš„æ ç›®å˜æˆæ¼«ç”»â€¦åƒæ˜¯è™šæ— ç¼¥ç¼ˆ...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-09-27</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-6015489225-oyyzz1sx9/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->ä¹…ä¿å²ç»ªé‡Œ<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;span &hellip;
    </a>
  </div>
</section>

</main>
</div>

<script async src="//yihui.name/js/center-img.js"></script>

<footer>

<div class="footer">
  <ul class="menu">
    
    <li><a href="/"><span data-hover="Home">Home</span></a></li>
    
    <li><a href="/about/"><span data-hover="About">About</span></a></li>
    
    <li><a href="/archives/"><span data-hover="Archive">Archive</span></a></li>
    
    <li><a href="/contributor/"><span data-hover="Contributor">Contributor</span></a></li>
    
    <li><a href="/index.xml"><span data-hover="Subscribe">Subscribe</span></a></li>
    
  </ul>
  
  <div class="copyright">Â© <a href="https://rainoffallingstar.github.io">Fallingstar</a> 2023 | <a href="https://github.com/rainoffallingstar">Github</a></div>
  
</div>
</footer>







</body>
</html>

